Aminosalicylic acid indications and usage: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} ; {{AE}} {{chetan}} | {{CMG}} ; {{AE}} {{chetan}} | ||
==INDICATIONS AND USAGE== | |||
PASER is indicated for the treatment of tuberculosis in combination with other active agents. It is most commonly used in patients with Multi-drug Resistant TB (MDR-TB) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. When PASER is added to the treatment regimen in patients proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PASER (AMINOSALICYLIC ACID) GRANULE, DELAYED RELEASE [JACOBUS PHARMACEUTICAL COMPANY, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Revision as of 18:34, 24 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
INDICATIONS AND USAGE
PASER is indicated for the treatment of tuberculosis in combination with other active agents. It is most commonly used in patients with Multi-drug Resistant TB (MDR-TB) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. When PASER is added to the treatment regimen in patients proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible.[1]
References
Adapted from the FDA Package Insert.